Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. - Wikidata - wikimedia - TriplyDB

Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations.

Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations.

http://www.wikidata.org/entity/Q39338784

about

Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.The phosphoinositide 3-kinase pathway and therapy resistance in cancer Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapy PI3K and cancer: lessons, challenges and opportunities Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention.Laser diode thermal desorption atmospheric pressure chemical ionization tandem mass spectrometry applied for the ultra-fast quantitative analysis of BKM120 in human plasma.PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.Modulation of thyroidal radioiodide uptake by oncological pipeline inhibitors and Apigenin NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5.PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization.PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment.Targeting PI3K in Cancer: Any Good News?Genetic changes in nonepithelial ovarian cancer.PI3K/AKT signaling pathway and cancer: an updated review.BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma.Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma.PI3K inhibitor enhances the cytotoxic response to etoposide and cisplatin in a newly established neuroendocrine cervical carcinoma cell line.Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.Development and characterization of a human orthotopic neuroblastoma xenograft.Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines.Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines.In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.Endometrial Carcinoma: Specific Targeted Pathways.PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance.Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma.The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis.Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors

P2860

Q26775940-E37662B2-4B12-464E-8092-57DF30AC48C8 Q27853088-C1FFCF65-BC07-49FA-ABDF-0F51464B1629 Q28082811-A3E4F0F8-EEE5-4759-A4C8-1840665096FA Q28548425-B6FCAE84-3967-4382-8B57-616AD93B9E7D Q29248893-426B017A-4A0E-4D32-A0F8-22EC96E1E470 Q30080017-6FD7967C-75FB-4451-B2F8-A7599C1FB376 Q30841629-78E478F3-9C4F-4D69-8AE6-C30A1294AF44 Q33462023-F5E649AE-4419-4A23-A313-F764FCF2401C Q33618630-40645CDC-F1DF-4987-A39B-1D4338C0B29F Q33744491-C4537BEA-CCE8-4DE2-AA6B-CC38FB76985E Q34461019-2DA9657E-43B2-40FB-8633-EBA055AE16FA Q34818301-BD8F8B49-CB6F-406F-9469-C3C61C27F865 Q35020913-00474BD7-583D-48DE-833A-454CFE230720 Q35784584-06894E47-F63F-4608-896F-435214767A55 Q35849961-8FED550B-89DD-439C-BD4E-8BF8B97786FD Q35948581-356F56A1-67D8-4E49-B695-7170FDD1E44F Q36379644-CECE5C79-D6AB-4EAF-A377-384864D96646 Q36552676-1A9933A1-E0C7-4805-BA2B-B5FE421BE225 Q37022406-1F7C641D-0371-440E-A80D-9D344B476479 Q37252398-EB79D947-F166-458E-A2D6-007F35D0A69B Q37384015-DC0AB045-3B3F-4247-84A9-CD119097219C Q37583378-CFF4D109-7F41-43B5-9150-A490DF0A440D Q37737793-5273F234-F1FE-4FE1-B575-8BD8DDA604F1 Q38105322-8BD6EA5E-2A19-4B77-B354-4AB5B4479BFE Q38123207-90791209-4722-4E49-8C73-01DAB198F510 Q38217651-76DD00B5-585E-4B71-8142-938D3DE470E3 Q38266139-6919E190-4325-4A47-9546-53648C982464 Q38618654-FBF167AD-2EF1-43A1-869F-A26CF8757A03 Q38704263-0A5F505B-713C-4A31-8615-D9784C003F8F Q38757645-8DD49576-7199-4F59-B5E6-62ECE056EFD9 Q38888609-713C7BED-65FF-4DA9-B557-1B64D122A68A Q38918345-D2109CC2-96A5-482F-B966-FAD0E462C306 Q38924965-E810331E-53B2-44AE-8522-C1CB222F1718 Q38956071-41DBD6E1-47B8-4863-A4E4-0F98A5AD71C7 Q38963261-0318D823-6A04-43D2-8A09-59CD9EB2BBD3 Q39026766-37FA6094-BC39-404D-9140-E9BF979A0278 Q39036088-792F21DA-6189-4FA2-A401-56720B52C67B Q39145770-214925DB-99C8-4508-A93A-5BEFE9B71DCD Q39170414-4C43AF77-3552-4BB9-8ECE-8A4974BB7CBF Q39735943-5BDA248A-1827-4040-92AB-05F29A3730F0

P2860

Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations.

http://www.wikidata.org/entity/Q39338784

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Characterization of the mechan ...... broad range of concentrations.

@en

Characterization of the mechan ...... broad range of concentrations.

@nl

type

label

Characterization of the mechan ...... broad range of concentrations.

@en

Characterization of the mechan ...... broad range of concentrations.

@nl

prefLabel

Characterization of the mechan ...... broad range of concentrations.

@en

Characterization of the mechan ...... broad range of concentrations.

@nl

P1433

Q39338784-8B935177-CFDD-408C-8895-77AAA21A5343

P1476

Q39338784-94D189B3-1F74-4EED-A19C-711272B6234E

P2093

Q39338784-0C4A46DB-9E10-4B6F-B7D5-13DC3F93DD2A

Q39338784-1205E0D9-DA72-44BD-A87C-F815182DFE96

Q39338784-13C656D0-2A07-4C52-AF53-B5D39C2824F4

Q39338784-24DE3FEC-290D-4418-BB14-39DADF26ABE3

Q39338784-28913732-4594-48F5-B33E-163129BF8674

Q39338784-38D2CED4-F0AC-4D6C-A689-28774A9E2C6C

Q39338784-39885272-629F-46B2-8D66-7D4933772981

Q39338784-51AAD4EC-AEE4-4F58-A3E6-C87E54ACC6E5

Q39338784-576610D4-2607-4E26-AD18-A64A38FF320E

Q39338784-67624F1D-4CFB-450B-84EE-4F5EE01C99E0

P304

Q39338784-F99E78E2-8D6F-4FF8-A868-EE215EA8F7EF

P31

Q39338784-709B3882-1A59-4CDE-BC69-054E0B32DFC7

P356

Q39338784-119421EE-7542-484C-8177-A7A05517DB1B

P433

Q39338784-BA9A5ADC-4935-4390-B6EA-1800FB722518

P478

Q39338784-B8648B64-A5F8-4788-9697-38B5DC0659D5

P577

Q39338784-6C623308-14D1-498D-BFF8-002BEA696B00

P5875

Q39338784-7516A87D-A2DD-4C7A-ADA6-FCF72CF39716

P698

Q39338784-8363D4D4-A504-4121-A758-2930B1B392F6

P921

Q39338784-480F6766-058B-47F5-8613-D2ADCAB35E78

P356

1535-7163.MCT-11-1021

P1433

Molecular Cancer Therapeutics

P1476

Characterization of the mechan ...... broad range of concentrations.

@en

P2093

Audrey Kauffmann

http://www.w3.org/2001/XMLSchema#string

Carlos Garcia-Echeverria

http://www.w3.org/2001/XMLSchema#string

Christine Fritsch

http://www.w3.org/2001/XMLSchema#string

Christopher Wilson

http://www.w3.org/2001/XMLSchema#string

Chrystèle Henry

http://www.w3.org/2001/XMLSchema#string

Daniel Alexander Guthy

http://www.w3.org/2001/XMLSchema#string

Dario Sterker

http://www.w3.org/2001/XMLSchema#string

Fabian Stauffer

http://www.w3.org/2001/XMLSchema#string

Francesco Hofmann

http://www.w3.org/2001/XMLSchema#string

Julia Kleylein-Sohn

http://www.w3.org/2001/XMLSchema#string

P304

1747-1757

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-11-1021

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225088516

http://www.w3.org/2001/XMLSchema#string

P698

22653967

http://www.w3.org/2001/XMLSchema#string

P921